Immunomodulatory effects of deacetylase inhibitors: Therapeutic targeting of FOXP3 + regulatory T cells

Nature Reviews Drug Discovery

Volumn 8, Issue 12, 2009, Pages 969-981

  Wang, Liqing ^a   De Zoeten, Edwin F ^a   Greene, Mark I ^b   Hancock, Wayne W ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 PHENYLIMIDAZOLE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CHR 3996; DEPSIPEPTIDE; ENZYME INHIBITOR; ETINOSTAT; EVP 0334; GIVINOSTAT; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; HYDROXAMIC ACID DERIVATIVE; M 344; MC 1293; MC 1568; MC 1575; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PCI 34051; ROMIDEPSIN; SYDX 275; TETRAPEPTIDE; TRANSCRIPTION FACTOR FOXP3; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

ACETYLATION; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BLEEDING; BRONCHUS HYPERREACTIVITY; CATALYSIS; CLINICAL TRIAL; COLITIS; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG TARGETING; ECG ABNORMALITY; ENTERITIS; EPILEPSY; FIBROSIS; GENE EXPRESSION; GLOMERULONEPHRITIS; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART MUSCLE ISCHEMIA; HEPATITIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY DISEASE; LYMPHOCYTE FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN STRUCTURE; PSORIASIS; QT PROLONGATION; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; STROKE; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; METHODOLOGY; ORGAN TRANSPLANTATION;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FORKHEAD TRANSCRIPTION FACTORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; ORGAN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY;

EID: 73449117582     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3031     Document Type: Review

References (168)

1. Kouzarides, T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176-1179 (2000).
2. Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Rev. Cancer 6, 38-51 (2006).
3. Sadoul, K., Boyault, C., Pabion, M. & Khochbin, S. Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie. 90, 306-312 (2008).
4. Spange, S., Wagner, T., Heinzel, T. & Kramer, O. H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int. J. Biochem. Cell Biol. 41, 185-198 (2009).
5. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840 (2009).
6. Li, B. et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl Acad. Sci. USA 104, 4571-4576 (2007).
7. Tao, R. et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Med. 13, 1299-1307 (2007).
8. Yang, X. J. & Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nature Rev. Mol. Cell Biol. 9, 206-218 (2008).
9. Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nature Rev. Genet. 10, 32-42 (2009).
10. Baur, J. A. & Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. Drug Discov. 5, 493-506 (2006).
11. Lavu, S., Boss, O., Elliott, P. J. & Lambert, P. D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nature Rev. Drug Discov. 7, 841-853 (2008).
12. Zhang, J. et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 1 Sep 2009 (doi:10.1172/JCI38902).
13. Villagra, A. et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nature Immunol. 10, 92-100 (2009).
14. Blanchard, F. & Chipoy, C. Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? Drug Discov. Today 10, 197-204 (2005).
15. Karagiannis, T. C. & El-Osta, A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21, 61-65 (2007).
16. Adcock, I. M. HDAC inhibitors as anti-inflammatory agents. Br. J. Pharmacol. 150, 829-831 (2007).
17. Brunkow, M. E. et al. Disruption of a new forkhead/ winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nature Genet. 27, 68-73 (2001).
18. Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genet. 27, 20-21 (2001).
19. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor FOXP3. Science 299, 1057-1061 (2003).
20. + regulatory T cells. Nature Immunol. 4, 330-336 (2003).
21. + T regulatory cells. Nature Immunol. 4, 337-342 (2003).
22. + regulatory T cells. J. Immunol. 180, 858-869 (2008).
23. Riley, J. L., June, C. H. & Blazar, B. R. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30, 656-665 (2009).
24. Chen, C., Rowell, E. A., Thomas, R. M., Hancock, W. W. & Wells, A. D. Transcriptional regulation by FOXP3 is associated with direct promoter occupancy and modulation of histone acetylation. J. Biol. Chem. 281, 36828-36834 (2006).
25. Samanta, A. et al. TGF-β and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proc. Natl Acad. Sci. USA 105, 14023-14027 (2008).
26. de Zoeten, E. F., Wang, L., Sai, H. & Hancock, W. W. HDAC9 as a therapeutic target in murine colitis. Gastroenterology (in the press).
27. Reilly, C. M. et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. J. Autoimmun 31, 123-130 (2008).
28. Saouaf, S. J. et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87, 99-104 (2009).
29. McDonel, P., Costello, I. & Hendrich, B. Keeping things quiet: roles of NuRD and Sin3 co-repressor complexes during mammalian development. Int. J. Biochem. Cell Biol. 41, 108-116 (2009).
30. Grozinger, C. M., Hassig, C. A. & Schreiber, S. L. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc. Natl Acad. Sci. USA 96, 4868-4873 (1999).
31. Fischle, W. et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45-57 (2002).
32. Lahm, A. et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl Acad. Sci. USA 104, 17335-17340 (2007). Fascinating explanation of why class IIa HDACs lack significant HDAC activity.
33. Jones, P. et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med. Chem. Lett. 18, 1814-1819 (2008).
34. Lemercier, C. et al. Class II histone deacetylases are directly recruited by BCL6 transcriptional repressor. J. Biol. Chem. 277, 22045-22052 (2002).
35. Zhang, C. L., McKinsey, T. A., Lu, J. R. & Olson, E. N. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor. J. Biol. Chem. 276, 35-39 (2001).
36. Zhang, C. L., McKinsey, T. A. & Olson, E. N. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol. Cell Biol. 22, 7302-7312 (2002).
37. Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
38. Chang, S., Bezprozvannaya, S., Li, S. & Olson, E. N. An expression screen reveals modulators of class II histone deacetylase phosphorylation. Proc. Natl Acad. Sci. USA 102, 8120-8125 (2005).
39. Berdeaux, R. et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nature Med. 13, 597-603 (2007).
40. Grozinger, C. M. & Schreiber, S. L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc. Natl Acad. Sci. USA 97, 7835-7840 (2000).
41. Han, A., He, J., Wu, Y., Liu, J. O. & Chen, L. Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. J. Mol. Biol. 345, 91-102 (2005).
42. McKinsey, T. A., Zhang, C. L. & Olson, E. N. Activation of the myocyte enhancer factor-2 transcription factor by calcium/calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5. Proc. Natl Acad. Sci. USA 97, 14400-14405 (2000).
43. Angelelli, C. et al. Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to DNA in skeletal muscle cells. Nucleic Acids Res. 36, 915-928 (2008).
44. Paroni, G. et al. PP2A regulates HDAC4 nuclear import. Mol. Biol. Cell 19, 655-667 (2008).
45. Wang, Z. et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 138, 1019-1031 (2009).
46. Valenzuela-Fernandez, A., Cabrero, J. R., Serrador, J. M. & Sanchez-Madrid, F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18, 291-297 (2008).
47. Richon, V. M. & O'Brien, J. P. Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment. Clin. Cancer Res. 8, 662-664 (2002).
48. Bottomley, M. J. et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J. Biol. Chem. 283, 26694-26704 (2008).
49. Schuetz, A. et al. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 283, 11355-11363 (2008).
50. Somoza, J. R. et al. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure 12, 1325-1334 (2004).
51. Vannini, A. et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101, 15064-15069 (2004).
52. Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nature Rev. Drug Discov. 5, 769-784 (2006).
53. Walkinshaw, D. R. & Yang, X. J. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr. Oncol. 15, 237-243 (2008).
54. Mai, A. & Altucci, L. Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 41, 199-213 (2009).
55. Gibson, P. R. The intracellular target of butyrate's actions: HDAC or HDON'T? Gut 46, 447-448 (2000).
56. Vezzani, A. & Granata, T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46, 1724-1743 (2005).
57. Rasheed, W., Bishton, M., Johnstone, R. W. & Prince, H. M. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev. Anticancer Ther. 8, 413-432 (2008).
58. Lee, M. J., Kim, Y. S., Kummar, S., Giaccone, G. & Trepel, J. B. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 20, 639-649 (2008).
59. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Rev. Drug Discov. 1, 287-299 (2002).
60. Richon, V. M., Garcia-Vargas, J. & Hardwick, J. S. Development of vorinostat: Current applications and future perspectives for cancer therapy. Cancer Lett. (2009).
61. Hu, E. et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307, 720-728 (2003).
62. Jones, P. et al. A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo. J. Med. Chem. 51, 2350-2353 (2008). (Pubitemid 351628496)
63. Massa, S. et al. 3-(4-aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors. J. Med. Chem. 44, 2069-2072 (2001).
64. Mai, A. et al. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem. 48, 3344-3353 (2005). (Pubitemid 40628053)
65. Muraglia, E. et al. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors. Bioorg Med. Chem. Lett. 18, 6083-6087 (2008).
66. Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M. & Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl Acad. Sci. USA 100, 4389-4394 (2003).
67. Balasubramanian, S. et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22, 1026-1034 (2008).
68. Kramer, O. H. et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22, 3411-3420 (2003).
69. Dokmanovic, M. et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther. 6, 2525-2534 (2007).
70. Scognamiglio, A. et al. HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2. Biochim. Biophys. Acta 1783, 2030-2038 (2008).
71. Backs, J., Backs, T., Bezprozvannaya, S., McKinsey, T. A. & Olson, E. N. Histone deacetylase 5 acquires calcium/calmodulin-dependent kinase II responsiveness by oligomerization with histone deacetylase 4. Mol. Cell Biol. 28, 3437-3445 (2008).
72. Shahbazian, M. D. & Grunstein, M. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76, 75-100 (2007).
73. Sobel, R. E., Cook, R. G., Perry, C. A., Annunziato, A. T. & Allis, C. D. Conservation of deposition-related acetylation sites in newly synthesized histones H3 and H4. Proc. Natl Acad. Sci. USA 92, 1237-1241 (1995).
74. + T cell responses. BMC Cancer 3, 30 (2003).
75. Gregoretti, I. V., Lee, Y. M. & Goodson, H. V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338, 17-31 (2004).
76. Chen, C. S., Weng, S. C., Tseng, P. H. & Lin, H. P. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879-38887 (2005).
77. Brogdon, J. L. et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 109, 1123-1130 (2007).
78. Leoni, F. et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl Acad. Sci. USA 99, 2995-3000 (2002).
79. Backdahl, L., Bushell, A. & Beck, S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int. J. Biochem. Cell Biol. 41, 176-184 (2009).
80. Nencioni, A. et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin. Cancer Res. 13, 3933-3941 (2007).
81. Bosisio, D. et al. Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J. Leukoc. Biol. 84, 1540-1548 (2008).
82. Sun, Y. et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J. Immunol. 182, 5899-5903 (2009).
83. Reddy, P. et al. Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J. Clin. Invest. 11 8, 2562-2573 (2008).
84. Matsuoka, H. et al. Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem. Pharmacol. 74, 465-476 (2007).
85. Matsuoka, H., Fujimura, T., Mori, H., Aramori, I. & Mutoh, S. Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. Int. Immunopharmacol. 7, 1422-1432 (2007).
86. Edens, R. E., Dagtas, S. & Gilbert, K. M. Histone deacetylase inhibitors induce antigen specific anergy in lymphocytes: a comparative study. Int. Immunopharmacol. 6, 1673-1681 (2006).
87. Huber, L. C. et al. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum. 56, 2755-2764 (2007).
88. Zhou, Q. et al. Histone deacetylase inhibitors blocked activation and caused senescence of corneal stromal cells. Mol. Vis. 14, 2556-2565 (2008).
89. Wang, Z. et al. SAHA-a potential epigenetic therapeutic agent for lung fibrosis? Eur. Respir. J. 12 Feb 2009 (doi:10.1183/09031936.00084808).
90. Yoshikawa, M., Hishikawa, K., Marumo, T. & Fujita, T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-β1 in human renal epithelial cells. J. Am. Soc. Nephrol. 18, 58-65 (2007).
91. Shan, B. et al. Requirement of HDAC6 for transforming growth factor-β1-induced epithelial-mesenchymal transition. J. Biol. Chem. 283, 21065-21073 (2008).
92. Glenisson, W., Castronovo, V. & Waltregny, D. Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation. Biochim. Biophys. Acta 1773, 1572-1582 (2007).
93. Choi, J. H. et al. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35, 89-96 (2005).
94. Camelo, S. et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 164, 10-21 (2005).
95. Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P. & Gilkeson, G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111, 539-552 (2003).
96. Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015-5022 (2006).
97. Nishida, K. et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50, 3365-3376 (2004).
98. Lin, H. S. et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150, 862-872 (2007).
99. Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus- leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921-3926 (2004).
100. Li, N. et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc. Natl Acad. Sci. USA 105, 4796-4801 (2008).
101. Granger, A. et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22, 3549-3560 (2008).
102. Marumo, T., Hishikawa, K., Yoshikawa, M. & Fujita, T. Epigenetic regulation of BMP7 in the regenerative response to ischemia. J. Am. Soc. Nephrol. 19, 1311-1320 (2008).
103. Kim, H. J. et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp. Ther. 321, 892-901 (2007).
104. Ryu, H. et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc. Natl Acad. Sci. USA 100, 4281-4286 (2003).
105. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041-2046 (2003).
106. Minamiyama, M. et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 13, 1183-1192 (2004).
107. Petri, S. et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 22, 40-49 (2006).
108. Parmigiani, R. B. et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc. Natl Acad. Sci. USA 105, 9633-9638 (2008).
109. Lin, T. et al. Histone deacetylase as therapeutic target in a rodent model of hemorrhagic shock: effect of different resuscitation strategies on lung and liver. Surgery 141, 784-794 (2007).
110. Sailhamer, E. A. et al. Acetylation: a novel method for modulation of the immune response following trauma/ hemorrhage and inflammatory second hit in animals and humans. Surgery 144, 204-216 (2008).
111. Alam, H. B. et al. Impact of resuscitation strategies on the acetylation status of cardiac histones in a swine model of hemorrhage. Resuscitation 76, 299-310 (2008).
112. Li, Y. et al. Cell protective mechanism of valproic acid in lethal hemorrhagic shock. Surgery 144, 217-224 (2008).
113. Vojinovic, J., Dinarello, C. A., Damjanov, N. & Oldoni, T. Safety and efficacy of oral ITF 2357 in patients with active systemic onset juvenile idopathic arthritis (SOJIA)-results of a phase II open label, international, multicentre clinical trial. Arthritis Rheum. 58, S943 (2008).
114. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
115. + regulatory T cells in the steady state. J. Exp. Med. 198, 737-746 (2003).
116. + regulatory T cells by TGF-β induction of transcription factor FOXP3. J. Exp. Med. 198, 1875-1886 (2003).
117. + regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201, 127-137 (2005).
118. + T cells. Int. Immunol. 18, 1607-1613 (2006).
119. + regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204, 1757-1764 (2007).
120. Sun, C. M. et al. Small intestine lamina propria dendritic cells promote de novo generation of FOXP3 T reg cells via retinoic acid. J. Exp. Med. 204, 1775-1785 (2007).
121. Heinonen, K. M. & Perreault, C. Development and functional properties of thymic and extrathymic T lymphocytes. Crit. Rev. Immunol. 28, 441-466 (2008).
122. + T cell-mediated suppression by dendritic cells. Science 299, 1033-1036 (2003).
123. +CD25 T cells. J. Immunol. 179, 2041-2045 (2007).
124. + regulatory T cells. Proc. Natl Acad. Sci. USA 105, 18460-18465 (2008).
125. + T regulatory cell-mediated suppression. Immunity 30, 636-645 (2009).
126. Izcue, A., Coombes, J. L. & Powrie, F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 27, 313-338 (2009).
127. + regulatory T cell function. Science 322, 271-275 (2008).
128. Tao, R., Wang, L., Murphy, K. M., Fraser, C. C. & Hancock, W. W. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J. Immunol. 180, 6649-6655 (2008).
129. Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
130. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225-1232 (2007).
131. Cobbold, S. P. et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc. Natl Acad. Sci. USA 106, 12055-12060 (2009).
132. Stroud, J. C. et al. Structure of the forkhead domain of FOXP2 bound to DNA. Structure 14, 159-166 (2006).
133. Li, B. et al. FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. Int. Immunol. 19, 825-835 (2007).
134. Zhou, Z., Song, X., Li, B. & Greene, M. I. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol. Res. 42, 19-28 (2008).
135. Bettelli, E., Dastrange, M. & Oukka, M. FOXP3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc. Natl Acad. Sci. USA 102, 5138-5143 (2005).
136. Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375-387 (2006).
137. Grant, C. et al. FOXP3 represses retroviral transcription by targeting both NF-kappa B and CREB pathways. PLoS Pathog 2, e33 (2006).
138. Ono, M. et al. FOXP3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446, 685-689 (2007).
139. Lee, S. M., Gao, B. & Fang, D. FOXP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111, 3599-3606 (2008).
140. Li, B. & Greene, M. I. FOXP3 actively represses transcription by recruiting the HAT/HDAC complex. Cell Cycle 6, 1432-1436 (2007).
141. + regulatory T cells with histone deacetylase inhibitors. Cell. Immunol. 257, 97-104 (2009).
142. + regulatory T-cell function and induce allograft tolerance. Immunol. Cell Biol. 87, 195-202 (2009).
143. + regulatory T cells differentiate into IL-17-producing cells. Blood 11 2, 2340-2352 (2008).
144. Kinugasa, F. et al. Effect of the immunosuppressant histone deacetylase inhibitor FR276457 in a canine renal transplant model. Transpl. Immunol. 21, 198-202 (2009).
145. Chung, Y. L., Lee, M. Y., Wang, A. J. & Yao, L. F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8, 707-717 (2003).
146. Mai, A. et al. Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. J. Med. Chem. 46, 4826-4829 (2003).
147. Jones, P. et al. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med. Chem. Lett. 18, 3456-3461 (2008). (Pubitemid 351728088)
148. Estiu, G. et al. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 51, 2898-2906 (2008).
149. Mai, A. et al. New pyrrole-based histone deacetylase inhibitors: Binding mode, enzyme-and cell-based investigations. Int. J. Biochem. Cell Biol. 41, 235-247 (2009).
150. Sengupta, N. & Seto, E. Regulation of histone deacetyl-ase activities. J. Cell Biochem. 93, 57-67 (2004).
151. Wong, R. H. et al. A role of DNA-PK for the metabolic gene regulation in response to insulin. Cell 136, 1056-1072 (2009).
152. + Treg function and induces long-term allograft survival. Am. J. Transplant 9, S621 (2009).
153. Hancock, W. W., Wang, L., de Zoeten, E. F., Bradner, J. E. & Mazitschel, R. HDAC6 is a key new epigenetic target for the enhancement of Treg production and function in vitro and in vivo. Am. J. Transplant 8, S223 (2008).
154. + regulatory T cells do not constitutively express IL-35. J. Immunol. 181, 6898-6905 (2008).
155. + T Regulatory cell-mediated suppression. Immunity 30, 636-645 (2009).
156. Gallimore, A. M. & Simon, A. K. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27, 5886-5893 (2008).
157. +CD25hi regulatory T cell-mediated suppression in patients with type 1 diabetes. Clin. Exp. Immunol. 154, 353-359 (2008).
158. D'Alise, A. M. et al. The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors. Proc. Natl Acad. Sci. USA 105, 19857-19862 (2008).
159. Strevel, E. L., Ing, D. J. & Siu, L. L. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J. Clin. Oncol. 25, 3362-3371 (2007).
160. Carducci, M. A. et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7, 3047-3055 (2001).
161. Kelly, W. K. et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578-3588 (2003).
162. Ryan, Q. C. et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23, 3912-3922 (2005).
163. Klimek, V. M. et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14, 826-832 (2008).
164. Barnes, P. J. Role of HDAC2 in the Pathophysiology of COPD. Annu. Rev. Physiol. (2008).
165. Adenuga, D., Yao, H., March, T. H., Seagrave, J. & Rahman, I. Histone deacetylase 2 is phosphorylated, ubiquitinated and degraded by cigarette smoke. Am. J. Respir. Cell. Mol. Biol. 40, 464-473 (2009).
166. Archin, N. M. et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 25, 207-212 (2009).
167. Bots, M. & Johnstone, R. W. Rational combinations using HDAC inhibitors. Clin. Cancer Res. 15, 3970-3977 (2009).
168. Wang, L., Tao, R., Friedlander, J. A. & Hancock, W. W. Tolerance without immunosuppression: Exploiting epigenetic regulation as a new approach to achieving donor-specific allograft tolerance. Am. J. Transplant 8, S203 (2008).